Darcilil with AI and pyrrotinib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (darcilil, an aromatase inhibitor, and pyrrotinib) for older adults with a specific type of advanced breast cancer that has both HER2 and hormone receptors. It aims to see if this mix works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- Your breast cancer has spread to other parts of the body (stage IV) and is both HER2-positive and hormone receptor-positive (called TPBC).
- You have not had any treatment for advanced breast cancer yet. If you had hormone therapy or anti-HER2 therapy in the past, it must have ended more than a year ago.
- Your overall health is good enough for daily activities (ECOG score 0-3).
- Your major organs (like blood, liver, kidneys, and heart) are working well, based on standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.